<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093221</url>
  </required_header>
  <id_info>
    <org_study_id>GTI1302</org_study_id>
    <nct_id>NCT02093221</nct_id>
  </id_info>
  <brief_title>Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of
      human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years
      old) and teens/adults (ages 12-35 years old) with new onset Type 1 Diabetes Mellitus (T1DM).
      Currently enrolling ages 12-35 only. Once 25 patients are randomized and data is reviewed
      enrollment will be opened to the child cohort. The purpose of this study is to evaluate the
      safety and efficacy of four dosing regimens of human plasma-derived alpha1-PI in T1DM.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide Area Under the concentration-time Curve (AUC)</measure>
    <time_frame>10 min pre-dose, immediately pre-dose, 15, 30, 60, 90, and 120 minutes post-dose</time_frame>
    <description>C-peptide concentration during mixed meal tolerance test with high protein energy drink. &quot;Dose&quot; for time frame refers to intake of high protein energy drink.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who discontinue due to Adverse Events (AEs)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for HbA1c levels</measure>
    <time_frame>Weeks 1 (Baseline), 14, 27, 39, 52, 69, 87, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycemic episodes</measure>
    <time_frame>104 weeks</time_frame>
    <description>Severe hypoglycemia defined according the ADA Workgroup on Hypoglycemia definition, as follows: An event requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alpha1-PI AUC</measure>
    <time_frame>Immediately prior to last infusion, immediately after, 15 and 30 minutes after, and 1, 3, 8, 24, 48, 120, 168, 240, 336, 408, and 504 hours after last investigation product infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean trough serum alpha1-PI</measure>
    <time_frame>Immediately prior to the Week 12 and 13 or Week 25 and 26 investigational product infusions</time_frame>
    <description>Blood samples for determination of trough total serum alpha1-PI concentration will be drawn prior to the Week 12 and 13 infusions or the Week 25 and 26 infusions depending on the randomized treatment group.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Alpha1-PI 180 mg/kg/wk, 26 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg/kg/wk Alpha1-PI, 26 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 26 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly infusions of placebo for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg/kg/wk Alpha1-PI, 13 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg/kg/wk Alpha1-PI, 13 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg/kg weekly infusions of Alpha1-PI for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 13 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly infusions of placebo for 13 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>180 mg/kg Alpha1-PI</intervention_name>
    <arm_group_label>Alpha1-PI 180 mg/kg/wk, 26 weeks</arm_group_label>
    <arm_group_label>180 mg/kg/wk Alpha1-PI, 13 weeks</arm_group_label>
    <other_name>Alpha1-antitrypsin</other_name>
    <other_name>Prolastin-C</other_name>
    <other_name>Alpha1-Proteinase Inhibitor (human), Modified Process</other_name>
    <other_name>Alpha-1 MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>90 mg/kg Alpha1-PI</intervention_name>
    <arm_group_label>90 mg/kg/wk Alpha1-PI, 26 weeks</arm_group_label>
    <arm_group_label>90 mg/kg/wk Alpha1-PI, 13 weeks</arm_group_label>
    <other_name>Alpha1-antitrypsin</other_name>
    <other_name>Prolastin-C</other_name>
    <other_name>Alpha1-Proteinase Inhibitor (human), Modified Process</other_name>
    <other_name>Alpha-1 MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo, 26 weeks</arm_group_label>
    <arm_group_label>Placebo, 13 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T1DM according to the ADA criteria.

          -  Current use of injected insulin therapy and one positive result on testing for any of
             the following antibodies (If not currently on insulin therapy, must have positive
             result for at least two of the below antibodies):

               -  Anti-islet-cell antibodies (islet cell antigen 512, insulinoma associated
                  protein 2),

               -  Anti-glutamic acid decarboxylase antibodies, or

               -  Anti-insulin antibodies (unless received insulin therapy for &gt; 7 days).

          -  Body Mass Index (BMI) ≤ 28 kg/m2 for adults (≥ 20 years of age) OR ≤ 90th percentile
             in accordance with the Centers for Disease Control BMI assessment for children and
             teens (2 through 19 years old).

        Exclusion Criteria:

          -  History of or current diabetic retinopathy, neuropathy, or nephropathy.

          -  Known thrombophilia or history of thrombosis.

          -  Malignant disease (including malignant melanoma; however, other forms of skin cancer
             are allowed) within five years of randomization.

          -  Active Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, or Human
             Immunodeficiency Virus infection.

          -  History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI
             preparation or other blood product(s).

          -  Known selective or severe Immunoglobulin A deficiency.

          -  Elevated liver enzymes (aspartate transaminase, alanine aminotransferase, and
             alkaline phosphatase) equal to or greater than 2.5 times the upper limit of normal.

          -  Therapy with exenatide or any other agents that stimulate pancreatic β cell
             regeneration or insulin secretion, or any antidiabetic agents (oral or parenteral)
             other than insulin within one month prior to screening.

          -  Use of omega-3 fatty acid supplements, including fish oil, within seven days prior to
             screening.

          -  Current or planned therapy with inhaled insulin, if it becomes available.

          -  Chronic use of systemic steroids, with the exception of inhaled steroids, above a
             stable dose equivalent to 5 mg/day prednisone (e.g., 10 mg every 2 days) within 4
             weeks prior to randomization. It is recommended to maintain the same dose throughout
             the study. (Note: Subjects with autoimmune conditions (i.e., asthma) necessitating
             treatment with systemic short-term corticosteroids and administered a rapid taper are
             eligible per protocol with the caveat that the tapering is complete or decreased to
             the minimum requirement (i.e., 5 mg/day) at least 1 week prior to the Baseline visit
             (when randomization occurs) to ensure the subject is stable. For longer term steroid
             usage, please consult the Grifols Medical Monitor before considering the subject for
             study participation.)

          -  Treatment with immunosuppressants or cytostatic agents within 6 months of
             randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica San Miguel</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Associates Medical Group</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Institute of America</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald H Chochinov MD</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCM Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barry J. Reiner MD, LLC.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico, Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Children's Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Associates Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Endocrinology, Genetics &amp; Metabolism</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital/Health Clinical Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research of San Antonio LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consano Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 26, 2017</lastchanged_date>
  <firstreceived_date>March 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Alpha1-Proteinase Inhibitor</keyword>
  <keyword>Beta Cell</keyword>
  <keyword>Alpha1-Antitrypsin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
